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Short summary 18	
The miR-132/212 cluster suppresses generation of IL-10-expressing Th1 cells 19	
during chronic infection. This is associated with miR-132/212-mediated 20	
suppression of ribosomal protein transcription in Th1 cells through silencing 21	
BTAF1 and p300.  22	
 23	
Highlights 24	
- The transcriptomic hallmark of miR-132/212 deficiency in splenic CD4+ T cells 25	
during chronic infection with Leishmania donovani is an up-regulation of several 26	
ribosomal protein genes. 27	
	 2	
- The miR-132/212 cluster controls ribosomal protein expression through directly 28	
targeting two transcriptional co-activators, BTAF1 and p300. 29	
- Leishmania donovani-infected miR-132/212-/- mice display increased IL-10 and 30	
reduced IFNg protein expression in Th1 cells, reduced hepatosplenomegaly, and 31	
increased parasite burdens.  32	
 33	
ABSTRACT 34	
Determining the mechanisms that distinguish protective immunity from 35	
pathological chronic inflammation remains a fundamental challenge. miR-132 has 36	
been shown to play largely immunoregulatory roles in immunity, however its role 37	
in CD4+ T cell function is poorly understood. Here, we show that CD4+ T cells 38	
express high levels of miR-132 and that T cell activation leads to miR-132 up-39	
regulation. The transcriptomic hallmark of splenic CD4+ T cells lacking the miR-40	
132/212 cluster during chronic infection is an increase in mRNAs levels of 41	
ribosomal protein (RP) genes. BTAF1, a co-factor of B-TFIID and novel miR-42	
132/212-3p target, and p300 contribute towards miR-132/212-mediated regulation 43	
of RP transcription. Following infection with Leishmania donovani miR-132-/- CD4+ 44	
T cells display enhanced expression of IL-10 and decreased IFNg. This is 45	
associated with reduced hepatosplenomegaly and enhanced pathogen load. The 46	
enhanced IL-10 expression in miR-132-/- Th1 cells is recapitulated in vitro 47	
following treatment with phenylephrine, a drug reported to promote ribosome 48	
synthesis. Our results uncover that miR-132/212-mediated regulation of RP 49	
expression is critical for optimal CD4+ T cell activation and protective immunity 50	
against pathogens. 51	
 52	
INTRODUCTION 53	
	 3	
MicroRNAs (miRNAs) are endogenous small silencing RNAs with fundamental roles in 54	
the immune system [1]. In this context, miR-132-3p (miR-132) is derived from the miR-55	
212/132 cluster and has emerged as key regulator of immune cell development and 56	
function [1, 2].  During innate immune activation, miR-132 is induced upon and plays a 57	
crucial role in the transcriptional response to pathogenic challenge [3-6]. We have 58	
previously shown that miR-132 is induced in a dose-dependent manner upon viral 59	
infection and suppresses the innate antiviral immune response by down-regulating 60	
expression of p300 (official symbol EP300), a necessary co-activator for several key 61	
transcription factors [3]. Furthermore, miR-132 has been shown to be critical for normal 62	
haematopoiesis and B cell development and function through suppression of FOXO3 63	
and SOX4, respectively [7, 8], whereas the miR-212/132 cluster has also been 64	
implicated in Th17 responses [9]. miR-132 is also up-regulated in a model of 65	
inflammation-induced cellular transformation [10], plays a key role inflammation during 66	
wound healing [11], is induced in vivo following infection by Toxoplasma gondii [12], and 67	
regulates macrophage activation following Mycobacterium tuberculosis infection [13]. 68	
Although the above studies have provided strong support for the role of miR-132 in the 69	
immune system, they have predominantly focused on acute inflammation or infection 70	
models whereas the role of miR-132 in models of pathogen-induced chronic 71	
inflammation remains poorly explored. For example, we have limited knowledge on 72	
whether miR-132 is dispensable for T cell-mediated immunity.  73	
 74	
Here we show that miR-132 is induced upon activation of CD4+ T cells in vitro and in 75	
vivo during infection of mice with Leishmania donovani (L. donovani). Using fully miR-76	
212/132-deficient mice [14] (hereafter referred to as miR-132-/- mice), we show that the 77	
transcriptomic hallmark of miR-132 deficiency in CD4+ T cells isolated from chronically 78	
infected spleens is an increase in mRNAs levels of ribosomal protein (RP) genes. 79	
Similarly, miR-132 controls RP gene mRNA levels during in vitro activation of CD4+ T 80	
cells. Enhanced ribosome biosynthesis during in vitro CD4+ T cell activation is thought 81	
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to be necessary for accommodating the needs for cytokine production in activated cells 82	
[15]. However, the in vivo relevance of this phenomenon and the molecular drivers 83	
underpinning it remain largely unexplored. Notably, miR-132 over-expression 84	
suppresses RP gene expression and protein synthesis rates in mouse embryonic 85	
fibroblasts (MEFs). Regulation of RP gene expression is mediated by miR-132-mediated 86	
silencing of proteins involved in transcription including p300 and BTAF1, which we 87	
identified here as a novel miR-132 target. In vivo, miR-132-/- CD4+ T cells from 88	
chronically infected mice express higher levels of IL-10 and lower levels of IFNγ when 89	
compared to WT cells. This functional impairment correlates with reduced 90	
immunopathology and increased pathogen burdens in L. donovani-infected miR-132-/- 91	
mice. In vitro, activated miR-132-/- CD4+ T cells treated with the hypertrophic factor 92	
phenylephrine (PE) also demonstrate enhanced IL-10 expression. Overall, the above 93	
demonstrate that miR-132 is a necessary and sufficient regulator of RP gene expression 94	
through targeting core transcriptional regulators and that this mechanism contributes 95	
towards optimal CD4+ T cell activation and protective immunity. 96	
 97	
RESULTS AND DISCUSSION 98	
miR-132 is up-regulated during CD4+ T cell activation 99	
We first determined whether miR-212/132 levels were regulated following stimulation of 100	
naïve (CD62L+ CD44-) CD4 T cells with anti-CD3 and anti-CD28 antibodies, and found 101	
strong miR-132-3p and -212-3p up-regulation that peaked at day 1 (18hrs) (Fig. 1A; ~20 102	
and ~30 fold increase compared to unstimulated cells) and remained elevated for at 103	
least 3 days. Expression of the miR-212/132 primary transcript is CREB-dependent [16], 104	
and as expected [17], TCR stimulation induced strong CREB phosphorylation within 2-105	
4 hours, and this was sustained for 3 days (Fig. EV1A). Whilst miR-146-5p showed little 106	
change following T cell activation, miR-155-5p was strongly up-regulated for sustained 107	
periods, whereas miR-16-5p levels declined (Fig. 1A). miR-132-3p and miR-212-3p up-108	
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regulation appeared to be a common feature in activated CD4+ T cells, and occurred 109	
regardless of T cell polarisation phenotype (Th0, Th1 and Th2; Fig. EV1B).  110	
To investigate the role of miR-212/132 in the development of inflammation and 111	
protective immune responses in vivo, we studied its expression in naïve and infected 112	
C57BL/6 WT mice with L. donovani amastigotes. This infection model allows the study 113	
of host-pathogen interactions [18], during which infection occurs in the liver, spleen, and 114	
bone marrow. We sorted splenic lymphocytes and found that CD4+ T cells express 115	
higher miR-132-3p levels than CD8+ T cells or B cells (Fig. 1B). Furthermore, L. 116	
donovani infection resulted in miR-132-3p up-regulation in CD4+ T cells. The extent of 117	
this up-regulation was similar to that observed for miRNAs previously reported to be 118	
involved in T cell responses such as 146-5p and 155-5p [19, 20]. Combining these 119	
results with previous findings demonstrating miR-132 induction downstream of TLR [3-120	
5] and the B cell receptor [7] establishes miR-132 induction as a hallmark of innate and 121	
adaptive immune activation. Of note, miR-132 up-regulation has also been observed in 122	
studies using human bulk CD4+ and CD8+ T cell populations where it was amongst the 123	
most prominent up-regulated miRNAs [21]. 124	
 125	
miR-212/132-deficiency is associated with global up-regulation of ribosomal 126	
protein genes in CD4+ T cells from chronically infected spleens. 127	
To gain a molecular understanding of the function of the miR-132/212 cluster in CD4+ T 128	
cells in vivo, we performed RNAseq analysis on biological replicates of sorted splenic 129	
CD4+ T cells from L. donovani-infected WT and miR-132-/- mice. Of the more than 14,000 130	
genes that were detectable in CD4+ T cells, similar numbers showed up- or down-131	
regulation by >50% in miR-132-/- compared to WT cells (Fig. 1C; 10.3% up and 10.6% 132	
down). However, of the 1290 significantly differently expressed genes (9% of total), 133	
approximately 2/3 (850) were up-regulated in miR-132-/- cells compared to WT and only 134	
1/3 (440) down-regulated. Pathway analysis of genes significantly up-regulated in miR-135	
132-/- mice (p<0.05, >50% regulation) using the Gene Set Enrichment Analysis [22] and 136	
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STRING tools [23] revealed that a cluster of RP genes was significantly over-137	
represented amongst genes upregulated in miR-132-/- CD4+ T cells (Fig. 1D and 1E). 138	
This up-regulation was evident for both small (RPS) and large (RPL) subunits protein 139	
genes and even pseudogene transcripts (Fig. 1F). These results were further validated 140	
by qPCR, showing an increase in all tested RP genes, reaching statistical significance 141	
for RPL27, RPS10 and RPL14-ps1 (Fig. 1G). To explore the significance of the 142	
observed increase in RP gene expression in miR-132-/- CD4+ T cells, we analysed 143	
published transcriptional profiles of in vitro generated Th1 and Th2 cells [24] and found 144	
that CD4+ T cell activation results in a statistically significant shift towards global up-145	
regulation of RP gene levels (Fig. 1H and Fig. EV1C). Taken together with previous 146	
reports demonstrating that activation of ribosome biosynthesis is associated with 147	
activation of CD8+ T cells [25] and production of cytokines by CD4+ T cells in vitro [15], 148	
our findings suggested that the observed RP gene up-regulation in miR-132-/- CD4+ T 149	
cells was a signature of enhanced activation. 150	
 151	
The B-TFIID cofactor BTAF1 is a direct miR-132 target in CD4+ T cells. 152	
To identify direct targets of the miR-132/212 cluster in CD4+ T cells, we performed 153	
RNAseq analysis of naïve CD4+ T cells from WT and miR-132-/- mice prior to and 154	
following 1 day (18 hours) of in vitro TCR stimulation under Th1 conditions. We focussed 155	
on Th1 responses as these predominate in L. donovani infection and these cells 156	
displayed the highest levels of miR-132 expression (Fig. EV1B). Broadly similar 157	
numbers of transcripts were detected in unstimulated and stimulated T cells (12336 and 158	
11140, respectively), with 5.0% (day 0 = 615) and 3.9% (day 1 = 432) showing significant 159	
differences between WT and miR-132-/- mice (Fig. 2A-B). A much larger number of 160	
genes (44% WT, 54% miR-132-/-) were differentially expressed when we compared 161	
naïve with activated T cells (Fig. EV2A-B). Of the genes that were significantly different 162	
between WT and miR-132-/- mice (p<0.05; 50% difference), 46% were up-regulated in 163	
miR-132-/- at day 0, and this increased to 68% at day 1. At day 1, we observed that the 164	
	 7	
majority of predicted miR-132/212-3p targets were up-regulated (i.e. 51/75 =68% 165	
displayed a positive log2 fold change) in miR-132-/- CD4+ T cells (Fig. 2C-D). Of note, a 166	
single predicted miR-132/212-3p target, BTAF1, was up-regulated in both unstimulated 167	
and activated miR-132-/- CD4+ T cells, as well as in CD4+ T cells from L. donovani-168	
infected miR-132-/- mice (Fig. 2C-E, and Fig. EV2C). Up-regulation of BTAF1 was 169	
confirmed by qPCR (Fig. 2F). BTAF1 protein expression was elevated in miR-132-/- 170	
CD4+ T cells compared to WT cells, both before and after TCR stimulation (Fig. 2G). 171	
BTAF1 contains a single 7mer-m8 site for miR-132/212-3p within its 3’UTR that is 172	
broadly conserved in mammals (Fig. EV2D). To assess whether BTAF1 was a direct 173	
target of miR-132/212-3p, we transfected HeLa or 3T3 cells with luciferase reporter 174	
constructs preceded by ~1.5kb of BTAF1 3’UTR (either WT or with miR-132/212-3p site 175	
mutated) in the presence of miR-132-3p or miR-212-3p mimics. This revealed that in the 176	
presence of miR-132-3p mimics, luciferase activity was significantly elevated following 177	
mutation of the miR-132/212 site in the 3’UTR (Fig. 2H, Fig. EV2E). A similar trend was 178	
observed in miR-212-3p transfected cells although this did not reach statistical 179	
significance. This demonstrated that miR-132 can directly interact with the predicted 180	
miR-132-binding site in the BTAF1 3’ UTR.  We also searched for potential miR-132-5p 181	
and miR-212-5p targets that were altered in miR-132-/- mice. Unlike miR-132-3p and 182	
miR-212-3p, these two miRNA differ in their seed sequence and so are predicted to 183	
have different mRNA targets (Fig. EV2F). Whilst several potential targets were 184	
significantly dysregulated in miR-132-/- CD4+ cells, there was little overlap between those 185	
altered in unstimulated T cells, d1 activated T cells or those derived from d28 L. 186	
donovani-infection (Fig. EV2G). Only a single target, BACH2 (predicted 7mer-A1 target 187	
for both miR-212-5p and miR-132-5p), was up-regulated by >50% in all three T cell 188	
datasets, but this was only significant for in vitro d1 stimulated T cells and was highly 189	
variable in the other two conditions (Fig. EV2H).  190	
Having observed an effect of miR-132 deletion on RP gene mRNA levels after chronic 191	
CD4+ T cell activation in vivo (Fig. 1), we tested whether we can observe a similar effect 192	
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in our dataset from the early stages of in vitro CD4+ T cell activation. Following 24h of in 193	
vitro activation of naïve CD4+ T cells, we observed that 40% of RP genes showed 194	
upregulation (positive log2 fold change or LFC) in WT mice. This proportion was 195	
significantly increased to 61% in miR-132-/- mice (P = 0.011) (Fig. EV2I). Furthermore, 196	
the vast majority of RP genes (81%) demonstrated a higher LFC (indicating stronger up-197	
regulation or weaker downregulation) upon activation of miR-132-/- CD4+ T cells 198	
compared to WT cells (Fig. EV2J). 199	
 200	
p300 and BTAF1 contribute to miR-132-mediated suppression of ribosomal 201	
protein expression 202	
miR-132 deficiency resulted in upregulation of several RP genes in CD4+ T cells from 203	
chronically infected mice with L. donovani (Fig. 1). In addition, we found that miR-132-204	
3p or miR-212-3p over-expression in mouse embryonic fibroblasts (MEFs) resulted in 205	
widespread down-regulation of RP gene mRNA levels (Fig. 3A and EV3A). These 206	
effects were confirmed at the protein level using Rpl27 and Rps10 as two representative 207	
RPs (Fig. EV3B). This allowed us to further probe the mechanism employed by miR-208	
132 to regulate ribosomal protein gene levels. The majority of RP transcripts up-209	
regulated in miR-132-/- mice (Fig. 1D) lacked miR-132/212-3p sites (13/15 coding 210	
transcripts), with the remaining 2/15 (RPL7L1 and RPL18) displaying non-conserved 211	
sites. Predicted miR-132/212-3p targets are statistically significantly enriched in proteins 212	
involved in transcription (Fig. EV3C). Therefore, we reasoned that the effect of miR-132 213	
on RP gene expression was caused by miR-132-mediated suppression of transcriptional 214	
regulators. For example, p300, a previously validated miR-132 target [3], is required for 215	
the activity of Sp1, YY1 and CREB, all of which have known roles in transcription of RP 216	
genes [26-28]. Of note, although miR-132 directly suppresses p300, its effects on p300 217	
mRNA steady-state levels are minimal [3]. In parallel, BTAF1, a predominant miR-132 218	
target in CD4+ T cells (Fig. 2) interacts with TATA-binding protein (TBP) to form B-TFIID, 219	
causing redistribution of TBP to new genomic sites [29, 30]. Over-expression of miR-220	
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132 in MEFs resulted in suppression of p300 and BTAF1 (Fig. 3B). Similarly, over-221	
expression of miR-132-3p or miR-212-3p in the EL4 T cell line also resulted in 222	
suppression of BTAF1 and p300 (Fig. EV3D) suggesting that both miRNAs contribute 223	
to regulation of BTAF1 and p300. Knockdown of p300 resulted in significant 224	
downregulation of several miR-132-regulated RP transcript levels, including RPL27, 225	
RPSA, RPS3A, RPS9, RPS10, and RPL14-ps1 (Fig. 3C), whereas levels of RPL18 226	
showed a trend towards downregulation (P=0.06). In addition, knockdown of BTAF1 227	
significantly reduced levels of RPL27 and RPL18, with RPL14-ps1 showing a trend 228	
towards downregulation (P=0.052) (Fig. 3D). Critically, suppression of RP expression 229	
by miR-132 was dependent on both p300 and BTAF1 (Fig. 3E). Although the majority 230	
of miR-132-mediated effects on RP expression were abolished upon knockdown of 231	
either p300 or BTAF1, we also identified RP mRNAs that were specifically dependent 232	
on p300 (e.g. miR-132-mediated suppression of Rps9) or BTAF1 (e.g. miR-132-233	
mediated suppression of Rpl18; Fig. 3E). To validate the functional relevance of these 234	
effects we tested protein synthesis rates in MEFs over-expressing miR-132-3p or miR-235	
212-3p using a puromycin incorporation assay [31]. Over-expression of either of the two 236	
miRNAs resulted in suppression of protein synthesis, consistent with their effect on RP 237	
expression (Fig. 3F). These findings demonstrate that p300 and BTAF1, two miR-132 238	
targets involved in transcription, contribute towards the widespread regulation of RP 239	
genes observed in miR-132/212-deficient or over-expressing cells. Interestingly, Mot1, 240	
the yeast homologue of BTAF1, promotes expression of ribosomal proteins in yeast [32], 241	
as seen here for BTAF1 and RPL27 and RPL18 in mouse cells. We should note that 242	
given the number of potential miR-132 targets involved in transcription (Fig. EV3C)[33], 243	
we cannot exclude the contribution of additional miR-132 targets towards RP gene 244	
regulation. Importantly, it is thought that the majority of RP genes are not regulated at 245	
the post-transcriptional level by miRNAs due their relatively short 3’UTRs [34]. However, 246	
our work demonstrates that a miRNA can indirectly suppress a cluster of RP genes in 247	
CD4+ T cells and MEFs. This reveals a novel mechanism of RP regulation with miR-132 248	
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acting as a molecular node mediating crosstalk between RP expression and post-249	
transcriptional gene silencing.  250	
 251	
The miR-212/132 cluster controls the balance between IL-10 and IFNγ production 252	
in CD4+ T cells. 253	
Having shown that miR-132 deficiency results in similar transcriptomic effects in CD4+ 254	
cells in vitro and in vivo (e.g. RP gene regulation, BTAF1 suppression) and during L. 255	
donovani infection (Figs. 1 and 2), we measured capacity for IFNγ and IL-10 production 256	
by CD4+ T cells from infected mice by intracellular cytokine staining following ex vivo 257	
stimulation with PMA and ionomycin. We found a modest but significant reduction in the 258	
ability of miR-132-/- CD4+ T cells to produce IFNγ (Fig. 4A). This was accompanied by 259	
a greater fold increase in production of IL-10 by miR-132-/- IFNγ+ CD4+ T cells compared 260	
to wild-type cells (Fig. 4B and Fig. EV4A). Interestingly, IL-10 mRNA levels were not 261	
statistically significantly different between WT and miR-132-/- cells (Fig. 4C), indicating 262	
that miR-132 affected IL-10 expression at the post-transcriptional/translational level. 263	
Increased IL-10 production by miR-132-/- CD4+ T cells was also evident following in vitro 264	
restimulation of splenic CD4+ T cells from infected mice with L. donovani antigen 265	
demonstrating that the effect was occurring in antigen-specific manner (Fig. EV4B). The 266	
observed reduction in frequency of IFNγ+ CD4+ T cells and an increase in frequency of 267	
IFNγ+IL-10+ CD4+ T cells is consistent with the concept that IL-10+ Th1 cells develop 268	
after prolonged exposure to antigen and represent an endpoint of the Th1 response [35]. 269	
In this respect, our results can be interpreted as miR-132-/- CD4+ T cells reaching this 270	
endpoint immunoregulatory status prematurely.   271	
At the molecular level, the increase in IFNγ+IL-10+ CD4+ T cells in vivo was associated 272	
with a transcriptomic signature characterised by an up-regulation of a cluster of RP 273	
genes in miR-132-/- CD4+ T cells (Fig. 1D-E). To further explore this finding we compared 274	
in vitro Th1 differentiation of WT and miR-132-/- CD4+ T cells in presence or absence of 275	
phenylephrine (PE), which has been shown to enhance ribosome biosynthesis [36]. 276	
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Remarkably, although there were no statistically significant differences between miR-277	
132-/- and WT cells, nor between WT DMSO-treated and PE-treated cells, treating miR-278	
132-/- CD4+ T cells with PE resulted in statistically significantly enhanced IL-10 279	
expression and increased number of cells compared to WT cells. An increase in IL-10 280	
levels was observed in PE-treated WT cells compared to DMSO-treated WT cells but 281	
this did not reach statistical significance. IFNg levels were not affected by PE and were 282	
lower in miR-132-/- Th1 cells although this did not reach significance after multiple testing 283	
correction (Fig. 4D-F). In agreement with our in vivo observations, the enhanced cell 284	
number and IL-10 expression under these in vitro conditions recapitulated enhanced 285	
activation and premature acquisition of an immunoregulatory state in miR132-/- CD4+ T 286	
cells. Overall, these results demonstrated that miR-132 connects RP expression, IL-10 287	
expression, and CD4+ T cell activation in Th1 cells. Our results infer that the observed 288	
deregulation of selected RPs in miR-132-/- CD4+ T cells in vivo likely alters the 289	
composition and function of ribosomes in a manner that specifically promotes IL-10 290	
expression. This could be potentially explained by formation of specialised ribosomes in 291	
activated CD4+ T cells [37, 38]. 292	
 293	
The miR-212/132 cluster promotes protective immunity to L. donovani. 294	
Having observed that loss of miR-132 favours an immunoregulatory (higher IL-10 295	
expression) phenotype in Th1 cells, we tested the response of miR-132-/- mice to L. 296	
donovani infection. Indeed, IFNγ+IL-10+ CD4+ T cells have been associated with immune 297	
dysregulation and infection susceptibility in a variety of human and experimental 298	
systems [39-43]. Furthermore, the role of IL-10 in preventing L. donovani clearance had 299	
been previously demonstrated [44-46]. However this support comes from the study of 300	
fully IL-10-deficient mice and use of blocking antibodies against IL-10 or its receptor. To 301	
determine whether modest changes in IL-10 levels could alter infection outcomes, we 302	
infected IL-10+/+, IL-10+/- and IL-10-/- mice. Infected IL-10+/- mice produced intermediate 303	
levels of IL-10 compared to their IL-10+/+ and IL-10-/- counterparts (Fig. EV5A), without 304	
	 12	
any change in IFNγ production (Fig. EV5B). Notably, as with WT mice treated with IL-305	
10R-blocking antibody or IL-10-/- mice, IL-10+/- mice were able to clear liver parasites 306	
albeit with slower kinetics (Fig. 5A). These experiments suggested that modifying the 307	
relative abundance of IL-10 and IFNγ by reducing IL-10 by 50% can affect susceptibility 308	
to L. donovani infection. Consistently with these findings and the observed IL-10 levels 309	
in miR-132-/- mice, L. donovani infection resulted in significantly elevated splenic 310	
parasite burdens in miR-132-/- mice (Fig. 5B). Although we observed variation in parasite 311	
load between different experiments (Fig. 5C), miR-132-/- spleens consistently harboured 312	
approximately 2-fold more parasites at day 28 compared to WT controls (Fig. 5C-D).  In 313	
addition to parasite loads miR-132 deficiency affected CD11b+ cell populations, here 314	
called MφΑ (CD11b+ F4/80+ CD11c-), MφB (CD11bhi F4/80hi CD11c+), and MφC 315	
(CD11bhi F4/80lo CD11c+) present in infected spleens (gated as Fig. EV5C). The 316	
numbers of MφA and MφB cells decreased in infected miR-132-/- mice characterised by 317	
higher IL-10 expression in CD4+ T cells (Fig. EV5D). Conversely, numbers of these 318	
populations increased in an IL-10 dose dependent manner, in infected IL-10-/- and to a 319	
lesser extent in IL-10+/- mice (Fig. EV5E), demonstrating that the number of these cells 320	
is inversely correlated with IL-10 expression. Of note, IL-10 expression did not differ 321	
between WT and miR-132-/- myeloid subpopulations (Fig. EV5F). This demonstrated 322	
that the effect of miR-132 on IL-10 expression does not occur in all IL-10-producing cell 323	
types, showing specificity for Th1 cells. Our findings do not exclude that miR-132-324	
mediated suppression of IL-10 might occur in other cell types (e.g. B cells, innate 325	
lymphoid cells) contributing to the overall function of miR-132 in immunity.   326	
Liver parasite burdens peaked around day 21 and we noted increased levels in miR-327	
132-/- mice at this time point (Fig. EV5G). Whilst miR-132-/- liver burdens were only 328	
significantly elevated at day 28 when we corrected for inter-experiment variations in 329	
infection intensity (Fig. EV5H), miR-132-/- mice continued to harbour a significantly 330	
elevated parasite burden at day 42 (Fig. EV5I), a time point when parasites are being 331	
cleared from this organ in WT C57BL/6 mice [18]. Notably, the enhanced pathogen 332	
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burdens coincided with significantly smaller spleen and liver size in miR-132-/- mice 333	
compared to their WT counterparts (Fig. 5E-F). The impact of miR-132 deficiency on 334	
hepatosplenomegaly was most pronounced at higher infection levels, with a similar 335	
trend also evident after infection with lower parasite doses (Fig. EV5J-K). 336	
In sum, we propose that our findings support a model according to which enhanced 337	
ribosomal protein expression upon activation of miR-132-/- CD4+ T cells in vivo 338	
contributes towards accelerated activation of these cells and the premature switch to 339	
the IFNγ+IL-10+ phenotype. Although we cannot exclude that other cell types or 340	
mechanisms contribute to the observed increase in parasite loads in miR-132-/- mice, 341	
we propose that the effects of miR-132 deficiency on IL-10 expression in IFNg+ CD4+ T 342	
cells significantly contribute to reduced protective inflammation and enhanced 343	
susceptibility of miR-132-/- mice to infection. This is consistent with previous publications 344	
that highlight that IL-10 produced by Th1 cells (rather than regulatory T cells or myeloid 345	
cells) is a critical determinant of L. donovani infection outcomes [40, 47]. Of note, due 346	
to the impossibility of concurrent physiological knockdown or over-expression of RPs, 347	
the functional relevance of this family of proteins to Th1 responses in vivo has remained 348	
elusive. Our results provide a novel conceptual framework for the in vivo relevance of 349	
RP expression in CD4+ T cells indicating that exaggerated RP expression can be 350	
associated with impaired T cell responses. We propose that miR-132-driven 351	
coordination of the machineries that control RNA metabolism is essential for optimal Th1 352	
cell activation and protective immunity. 353	
 354	
MATERIALS AND METHODS 355	
Ethics 356	
Animal care and experimental procedures were regulated under the Animals (Scientific 357	
Procedures) Act 1986 (revised under European Directive 2010/63/EU) and were 358	
performed under UK Home Office License (project licence number PPL 60/4377 with 359	
approval from the University of York Animal Welfare and Ethical Review Body). Animal 360	
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experiments conformed to ARRIVE guidelines. 361	
 362	
Mice and L. donovani infection 363	
Female C57BL/6 CD45.1, CD45.2, and RAG2-/- mice were obtained from Charles River 364	
(UK). MiR-132/212-/- mice (complete knockouts) were provided by Dr Richard Goodman 365	
(Vollum Institute, Oregon Health & Science University, USA). IL-10-/- mice were provided 366	
by Dr Anne O’Garra (Francis Crick Institute, UK) and were crossed with WT CD45.2 367	
C57BL/6 mice to generate IL-10+/- heterozygotes. All mice were bred in house, 368	
maintained under specific pathogen-free conditions and used at 6 – 12 weeks of age. 369	
The Ethiopian strain of L. donovani (LV9) was maintained by passage in RAG-2-/- mice. 370	
Mice were infected i.v. with 100x106 amastigotes via the tail vein. Parasite doses of 10 371	
and 30x106 were also used where indicated. Parasite burden was expressed as 372	
Leishman-Donovan units (LDU; the number of parasites per 1,000 host cell nuclei × 373	
organ weight in mg)[48]. To allow comparison between these experiments, we 374	
normalised LDU to the levels observed in WT mice (relative LDU). For IL-10R 375	
neutralisation experiments mice were infected with L. donovani and received anti-IL10R 376	
(Clone: 1B1.3A from Bio X Cell) or IgG isotype control (SIGMA) injections at day 0, 14, 377	
and 21 p.i. at 0.5mg mAb/injection. 378	
  379	
FACS analysis and cell sorting. 380	
For FACS analysis, spleens were first digested with 0.4 U/ml Liberase TL (Roche) and 381	
80 U/ml DNase I type IV in Hank’s Balanced Salt Solution (both Sigma) for 15min at 382	
37oC. Enzyme activity was inhibited with 10mM EDTA pH 7.5 and single cell 383	
suspensions created with 70 μm nylon filters (BD Biosciences) in complete RPMI 1640 384	
(ThermoFisher) supplemented with 10% heat inactivated FCS (HyClone), 100 U/ml 385	
penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine (all ThermoFisher). Red blood 386	
cells were lysed with red blood cell lysing buffer (Sigma), For live/dead discrimination, 387	
cells were washed twice in PBS, then stained with Zombie Aqua (Biolegend) before 388	
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resuspension in FACS buffer (PBS containing 0.5% BSA and 0.05% azide). Fc 389	
receptors were blocked with 100μg/ml rat IgG (Sigma) for 10min at 4oC, before surface 390	
staining for 30min at 4oC. Combinations of the following anti-mouse antibodies were 391	
used: CD45.1 APC (clone A20); CD45.2 BV786 (104); CD3 FITC (145-2C11); B220 392	
FITC (RA3-6B2); TCRβ PE-Cy7 (H57-597); MHCII alexa700 (M5/114.15.2); Ly6G PE-393	
Cy7 (1A8); CD11b PB and APC (M1/70); CD11c PerCP/Cy5.5 (N418); F4/80 FITC and 394	
alexa647 (BM8); CD44 FITC (IM7); CD62L PE (MEL-14); CD8α APC (53-6.7); CD4 PE 395	
and PerCP/Cy5.5 (RM4-5); IFNγ FITC (XMG1.2); IL-10 PE (JES5-16E3). All antibodies 396	
were from Biolegend. To measure intracellular cytokines in T cells following ex vivo 397	
stimulation, cells were first stimulated in complete RPMI for 4 hours at 37oC with 398	
500ng/ml PMA, 1μg/ml ionomycin and 10μg/ml brefeldin A (all Sigma). For myeloid cells, 399	
cells were cultured as above either in the absence of exogenous stimulation (brefeldin 400	
A alone) or with E. coli O55:B5 LPS (1μg/ml with brefeldin A; Sigma). To measure 401	
antigen-specific cytokine production, CD4+ cells were purified by magnetic separation 402	
(Miltenyi Biotech) from the spleens of day 28 L. donovani infected CD45.2 WT and miR-403	
132-/- mice and cultured for 3 days with naïve splenocytes (CD45.1 WT mice) as a source 404	
of antigen-presenting cells (0.5x106 CD45.2+ Ld CD4+, 1x106 CD45.1+ naïve 405	
splenocytes). Cells were cultured either alone or with 1.5x107 whole killed (freeze-406	
thawed) L. donovani amastigotes as a source of parasite antigen. Brefeldin A was added 407	
as above for the final 4 hours of culture to permit accumulation of intracellular cytokines. 408	
CD45.2 and CD45.1 staining was used to assess cytokine production by CD4 T cells 409	
from L. donovani-infected and naïve mice, respectively. For all intracellular cytokine 410	
staining, surface stained cells were fixed and permeabilised (20min at 4oC) using 411	
Fixation/Permeabilisation solution before washes in Perm/Wash buffer (both BD 412	
Biosciences). Cells were then staining with intracellular antibodies as above except in 413	
Perm/Wash buffer. Appropriate isotype controls were included. For FACS analysis, 414	
events were acquired on a LSRFortessa (BD Biosciences) before analysis with FlowJo 415	
(FlowJo LLC). For cell sorting of splenic lymphocytes from naïve and Ld-infected 416	
	 16	
spleens, B cells were gated as B220+ CD3-; CD4 T cells as B220- CD3+ CD4+ CD8a-; 417	
and CD8 T cells as B220- CD3+ CD4- CD8α+. For purification of naïve and activated CD4 418	
T cells from uninfected mice, single cell suspensions were prepared from pooled 419	
spleens and peripheral LN (axillary, brachial and inguinal). CD4+ cells were enriched 420	
using CD4 microbeads and LS columns (both Miltenyi Biotec) before cell sorting of naïve 421	
CD4 T cells (CD4+ CD62L+ CD44- CD11b- CD8a- MHCII-). For cell sorting of splenic 422	
myeloid cell populations, cells were gated as Fig. EV5C. Cell sorting was performed with 423	
a MoFlo Astrios (Beckman Coulter) and sorted cells were typically >98% positive. 424	
 425	
In vitro activation of CD4 T cells 426	
Purified CD4 T cells were stimulated with 10μg/ml plate bound anti-CD3ε (clone 145-427	
2C11) and 2μg/ml soluble anti-CD28 (37.51) in RPMI 1640 as before in flat bottom 96 428	
well plates. For Th1 polarisation, cells were also treated with 15ng/ml recombinant 429	
mouse IL-12 and 5μg/ml anti-IL-4 (11B11), or for Th2 polarisation, 30ng/ml recombinant 430	
mouse IL-4 and 5μg/ml anti-IFNγ (XMG1.2). Phenylephrine hydrochloride (Sigma) was 431	
used at 10μM and added during both anti-CD3 dependent activation (4 days) and also 432	
during rest in 10U/ml recombinant human IL-2 (2 days). All antibodies were from 433	
Biolegend and were low endotoxin / azide free, and recombinant cytokines were from 434	
Peprotech. 435	
 436	
MEF cell culture, siRNA and miRNA mimic treatment 437	
C57BL/6 MEFs were provided by Dr. D. Coverley (University of York, UK) and were 438	
cultured in DMEM (high glucose and pyruvate; ThermoFisher) supplemented with 10% 439	
FCS, pen-strep and L-glut as RPMI. For transfections, 5x104 cells per well were seeded 440	
in 6 well plates and transfected the next day with ON-TARGETplus SMARTpool siRNA 441	
(100nM), miRIDIAN miRNA mimics (50nM), or appropriate controls (all Dharmacon, GE 442	
Healthcare) using TransIT-siQUEST transfection reagent (Mirus) and Opti-MEM 443	
medium (ThermoFisher) for 6 hours before being replaced with complete DMEM. EL4 444	
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cells were grown in RPMI supplemented with 10% FCS and were transfected with 445	
miRNA mimics using Neon Nucleofection as per manufacturer’s instructions. Non-446	
targeting control (NTC) siRNAs or mimics were used as controls. Cells were harvested 447	
48 hours after transfection. 448	
 449	
Quantitative reverse transcription PCR (qRTPCR) 450	
RNA was extracted from tissue samples or purified cell populations using QIAzol and 451	
miRNeasy RNA extraction kits (QIAGEN) according to manufacturer’s instructions. 452	
Tissue samples were first dissociated in QIAzol using a Tissuelyser LT with stainless 453	
steel beads (all QIAGEN, UK). For detection of mature miRNA, cDNA was synthesised 454	
using Taqman miRNA reverse transcription kits, and levels determined with Taqman 455	
miRNA assays and Taqman Universal PCR Master Mix (all ThermoFisher). For mRNA 456	
transcripts, reverse transcriptions were carried out with Superscript III (ThermoFisher) 457	
and random hexamer primers (Promega), and measured with Fast SYBR Green Master 458	
Mix (ThermoFisher). PCR were performed using a StepOnePlus Real Time PCR 459	
System (ThermoFisher) and relative transcript levels determined using the ∆∆Ct method. 460	
Mature miRNA levels were normalised to U6. RNA transcript levels in T cells from L. 461	
donovani-infected mice and MEFs were normalised to HPRT. As in vitro CD4 T cell 462	
activation changes HPRT, GAPDH and β-actin expression levels, U6 was also used to 463	
normalise mRNA expression in day 0 and 1 naïve T cells. The following primer 464	
sequences were used:  465	
BTAF1: Forward: 5’GCCTTTGGAAAGCTTTTGTG3’, Reverse: 466	
5’CCAGTACCTGCCCCATGT3’. HPRT: Forward: 467	
5’GCGTCGTGATTAGCGATGATGAAC3’, Reverse: 468	
5’ATCTCCTTCATGACATCTCGAGCAAGTC3’. POLR2F: Forward: 469	
5’GAGGAGGACGAAGGACTTGA3’, Reverse: 5’CCAGATGGGAGAATCTCGAC3’. 470	
RPL12: Forward: 5’CGAAGATCGGTCCTCTGG3’, Reverse: 471	
5’AATTCTGAGACCCTTCCAGTCA3’. RPL18: Forward: 472	
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5’CGCATGATCCGAAAGATGA3’, Reverse: 5’AACTTCCAGAATCCGCACAT3’. 473	
RPL26: Forward: 5’AGAAGGCTAATGGCACAACC3’, Reverse: 474	
5’TCCAGCTTTAGCCTGGTGAT3’. RPL27: Forward: 475	
5’TGAAAGGTTAGCGGAAGTGC3’, Reverse: 5’CATGAACTTGCCCATCTCG3’. 476	
RPL8: Forward: 5’CAACAGAGCCGTTGTTGGT3’,  Reverse: 477	
5’CAGCCTTTAAGATAGGCTTGTCA3’. RPS10: Forward: 478	
5’GTGAGCGACCTGCAAGATTC3’, Reverse: 5’CAGCCTCAGCTTTCTTGTCA3’. 479	
RPS14: Forward: 5’AGTCTGGAGACGACGATCAGA3’, Reverse: 480	
5’CAGACACCAAACACATTCTCTCC3’. RPS30: Forward: 481	
5’GGTCGCCCAGATCAAAGAT3’, Reverse: 5’TGCCAGAAGCACGACTTG3’. RPS3A: 482	
Forward: 5’TGGCAAGAAGGGAGCTAAGA3’, Reverse: 483	
5’GTGTCTTCCCGATGTTCCTAAT3’. RPS9: Forward: 484	
5’ATCCGCCAACGTCACATTA3’, Reverse: 5’TCTTCACTCGGCCTGGAC3’. RPSA: 485	
Forward: 5’GGTCCATACGGCGTTGTT3’, Reverse: 486	
5’GCAGCAAGGAATTTGAGGAC3’. RPL14-ps1: Forward: 487	
5’TGCTGCTGCTGCTAAAGCTA3’, Reverse: 5’CAGCCTTCTTGCCTGGTC3’. RPL23-488	
ps3: Forward: 5’ATAAGGCCCGACGGAGAG3’, Reverse: 489	
5’GAATTAGCCATCTGGACTCAGTTT3’. 490	
 491	
SDS-PAGE, Western blotting, and protein synthesis assays 492	
Cells were washed twice in PBS and protein extracts prepared in RIPA buffer (150mM 493	
NaCl, 10mM Tris pH 7.2, 5mM EDTA, 0.1% SDS, 0.1% Triton X-100, 1% sodium 494	
deoxycholate, 1mM PMSF, 1% Protease Inhibitor cocktail P8340, 1% Phosphate 495	
Inhibitors cocktails 2 and 3; all Sigma). Equal total amounts of protein were resolved on 496	
SDS-PAGE gels and transferred to PVDF membranes (Millipore) using a BioRad SD 497	
Semidry Transfer Cell, blocked for 2 hours at room temperature in 2% BSA 498	
(ThermoFisher) or 5% milk powder (Sigma) in TBST (150mM NaCl, 7.7mM Tris HCl pH 499	
8, 0.1% Tween 20; all Sigma) before overnight probing with primary antibodies at 4oC. 500	
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Antibodies were as follows: total CREB (clone 48H2), p-CREB S133 (87G3), BTAF1 501	
(rabbit pAb #2637; all Cell Signaling Technology), p300 (clone NM11), Rpl27 (14980-1-502	
AP, Proteintech), Rps9 (14894-1- AP, Proteintech), β-actin (AC-15), GAPDH (9484; all 503	
Abcam). Following extensive washing in TBST, blots were incubated with secondary 504	
antibodies (goat anti-rabbit or mouse HRP; DAKO) for 1 hour at room temp, washed as 505	
before, and developed with ECL Western Blotting Detection Reagent and Hyperfilm ECL 506	
(both GE Healthcare). Densitometry was performed using Fiji / ImageJ.  507	
Protein synthesis rates were measured by puromycin incorporation [31]. Cells were 508	
pulsed for 10 mins with 10µg/ml puromycin (Sigma) and then washed and incubated for 509	
an extra 50 mins before lysed and used for western blotting analysis. Puromycin was 510	
detected with the monoclonal antibody clone 12D10 (Merck Millipore). 511	
 512	
RNA sequencing analysis 513	
Sequence reads were trimmed to remove adaptor sequences with Cutadapt and 514	
mapped to mouse genome GRCm38 with HISAT2[49] including “rna-strandness FR” 515	
option. Data available at GEO, accession number GSE125268. Transcriptome 516	
assembly and quantification was performed using the Tuxedo pipeline (version 517	
2.2.1)[50]. Cufflinks was used to assemble transcriptomes for each sample using the 518	
GTF annotation file for the GRCm38 mouse genome. This was followed by running 519	
Cuffmerge to merge individual sample transcriptomes into full transcriptomes. 520	
Quantification and normalisation were carried out for each experiment using Cuffquant 521	
and Cuffnorm. Differential expression on gene FPKM values was performed by 522	
conducting paired and independent t-tests with Benjamini-Hochberg false discovery rate 523	
correction. GSEA (http://software.broadinstitute.org/gsea) and STRING analysis 524	
(http://string-db.org/) were performed where indicated. For analysis of genes 525	
differentially expressed between WT and miR-132-/- CD4 T cells from Ld-infected 526	
spleens, transcripts were required to be significantly dysregulated (>50% change from 527	
WT levels, p<0.05) with FPKM values>1, and STRING settings were highest confidence 528	
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interactions only excluding text mining. Targetscan (http://www.targetscan.org/vert_71/) 529	
was used to predict targets of miRNA from the miR-212/132 cluster (cumulative 530	
weighted context score++ <-0.1). 531	
 532	
Luciferase assays 533	
BTAF1 3’UTR was amplified from mouse spleen cDNA (reverse transcribed with 534	
Superscript II and oligo-dT primers; both ThermoFisher) using the following primers : 535	
forward 5’CTCGAGTGCAACTGCTGCTAGCTCAGTTA3’ (which introduces 5’ Xho I 536	
site) and reverse 5’GCGGCCGCTTATGAAAGCAGACAAGTA3’ (which introduces 3’ 537	
Not I site). The 1.5 kb amplicon, which encompasses most of the 3’ UTR of BTAF1 538	
minus a 25nt 5’ GC rich stretch, was cloned into pGEM-T vector (Promega) and 539	
sequence verified. We also performed site directed mutagenesis to remove the miR-540	
212/132 seed sequence using QuikChange Site-Directed Mutagenesis (Agilent) with the 541	
following primer pairs : 542	
5’CTGAACCCTGTGGTAAAGACTAAATACTGTAGCAGGGCCTGAAGC3’ and 543	
5’GCTTCAGGCCCTGCTACAGTATTTAGTCTTTACCACAGGGTTCAG3’, resulting in 544	
mutation of WT sequence (5’AACCCUGUGGUAAAGACUGUUU3’) to mutant 545	
(5’AACCCUGUGGUAAAGACUAAAU3’). Inserts were excised with XhoI and NotI 546	
(NEB) and ligated into psiCHECK-2 (Promega). Luciferase assays were performed in 547	
HeLa and 3T3 cells 24 hours after transfection as previously described[3]. 548	
 549	
Statistical analysis 550	
Statistical analyses were carried out as indicated with Prism 5 (Graphpad Software Inc). 551	
Two-way comparisons used paired or unpaired t-tests as indicated and multiple 552	
comparisons used one-way ANOVA, followed by Bonferroni correction for multiple 553	
testing. P values of <0.05 were considered significant. * p<0.05, ** p<0.01, *** p<0.001, 554	
**** p<0.0001. Statistical significance in enrichment of RP genes (as in Fig. 2I) were 555	
determined using Chi-Square test. 556	
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FIGURE LEGENDS 737	
Figure 1: The miR-132/212 cluster regulates RP mRNA levels in CD4+ T cells from 738	
chronically infected spleens. 739	
A. Expression of indicated miRNAs in sorted naïve (CD62L+ CD44-) CD4+ T cells and 740	
following in vitro stimulation with anti-CD3 / anti-CD28 (1-3 days), relative to levels in 741	
cells prior to stimulation. Data from 3 independent experiments each using T cells pooled 742	
from 4 WT mice. Significance determined by one-way ANOVA. 743	
B. Expression of indicated miRNAs in purified spleen lymphocytes (B cells, CD4+ T cells 744	
and CD8+ T cells) from d0 naive (white) and day 28 L. donovani-infected (grey) mice. 745	
Expression of each miRNA normalized to levels in whole naïve spleen (dotted line). Data 746	
is mean + SEM of 2 experiments with cells purified from 3-5 pooled spleens. 747	
C. Volcano plot of RNAseq gene expression in splenic WT and miR-132-/- CD4+ T cells 748	
from d28 L. donovani infected mice. Fold change determined as log2 mean FPKM (miR-749	
132-/-/WT) from 4 WT and 5 miR-132-/- mice. Transcripts significantly different between 750	
WT and miR-132-/- (p<0.05) are shown in red. Dotted box indicates transcripts 751	
significantly up-regulated in miR-132-/- CD4+ T cells by more than 50%. 752	
D. STRING network analysis of significantly up-regulated transcripts in CD4+ T cells 753	
from spleen of d28 L. donovani infected miR-132-/- mice compared to WT cells. Cluster 754	
of ribosomal proteins shown in green circle, with coding RP transcripts (black) and 755	
pseudogenes (red) indicated. Secondary clusters are shown in grey. 756	
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E. Top enriched molecular function Gene Ontology terms for genes significantly up-757	
regulated in CD4+ T cells from spleens of infected miR-132-/- mice compared to WT mice. 758	
F. Volcano plot of all RP genes in splenic WT and miR-132-/- CD4+ T cells from d28 L. 759	
donovani infected mice. RPL genes  are shown as circles, RPS genes as triangles, and 760	
pseudogenes as squares. Red symbols indicate significant difference between WT and 761	
miR-132-/- cells (p<0.05) whereas black non-significant.  762	
G. Expression of RP transcripts determined by qPCR from L. donovani infected d28 WT 763	
(blue) and miR-132-/- mice (red). N=9 for each WT and miR-132-/- from 2 independent 764	
infection experiments. Box extends from 25-75th percentile, whiskers are minimum and 765	
maximum values, and horizontal lines indicate median. Significance determined by 766	
unpaired t-test. 767	
H. Fold change of all RP transcripts (grey) in Th1 cells compared to naïve CD4+ T cells. 768	
Data taken from RNA sequencing experiments described in reference 24. Fold changes 769	
in IL-10 (red) and IFNγ (blue) indicated for comparison. The statistical significance of 770	
the observed up-regulation of RP transcripts in Th1 cells is determined by Chi-squared 771	
test. 772	
Data information: * p<0.05, ** p<0.01, *** p<0.001. 773	
 774	
Figure 2: The B-TFIID cofactor BTAF1 is a direct miR-132 target in CD4+ T cells. 775	
A. Volcano plot (Log2(Fold Change) vs -Log(P value)) of RNA gene expression in 776	
purified naïve CD62L+ CD44- WT and miR-132-/- CD4+ T cells. Fold change determined 777	
as log2 mean FPKM (miR-132-/-/WT) from 4 WT and 4 miR-132-/- mice. Transcripts 778	
significantly different between WT and miR-132-/- cells (p<0.05) shown in red.  779	
B. Volcano plot of RNA gene expression in purified naïve CD62L+ CD44- WT and miR-780	
132-/- CD4+ T cells following 18hr in vitro stimulation with anti-CD3/anti-CD28 under Th1 781	
conditions. Fold change determined as log2 mean FPKM (miR-132-/-/WT) from 4 WT 782	
and 4 miR-132-/- mice. Transcripts significantly different between WT and miR-132-/- cells 783	
(p<0.05) shown in red.  784	
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C. Volcano plot of transcripts containing a conserved miR-212/132-3p target site in 785	
naïve CD4+ T cells from WT or miR-132-/- mice. 786	
D. Volcano plot of transcripts containing a conserved miR-212/132-3p target site in in 787	
vitro polarised (Th1 condtions, 18h post stimulation) CD4+ T cells from WT or miR-132-788	
/- mice. 789	
E. Volcano plot of transcripts containing a conserved miR-212/132-3p target site in 790	
spleen CD4+ T cells from d28 L. donovani infected WT or miR-132-/- mice. 791	
F. BTAF1 transcript levels determined by qRTPCR in WT (blue) or miR-132-/- (red) in 792	
naïve (d0) and Th1 polarised for 18h (d1) CD4+ T cells, and CD4+ T cells from d28 L. 793	
donovani infected WT or miR-132-/- mice. N=8-9 for each WT and miR-132-/-.  794	
G. Expression of BTAF1 protein in d0 naïve and d1 (18hr) Th1-polarised WT and miR-795	
132-/- CD4+ T cells, as determined by Western blot. Each lane from individual mouse, 796	
and representative of two independent experiments. 797	
H. Relative luciferase activity in HeLa transfected with plasmid containing WT BTAF1 798	
3’UTR (white) or BTAF1 3’UTR on which the miR-132 binding site is mutated (grey) 799	
downstream of renilla luciferase, in the presence of miR-132-3p or miR-212-3p mimics. 800	
Error bars indicate SEM from eight replicate treatments. 801	
Data information: Significance in (F) and (H) determined by unpaired t-test. * p<0.05, ** 802	
p<0.01. 803	
 804	
 805	
Figure 3: miR-132 and its targets p300 and BTAF1 control RP expression. 806	
A. mRNA levels of indicated RP transcripts determined by qRTPCR in MEFs transfected 807	
with Non-targeting control (NTC) mimics (white) or miR-132-3p mimics (grey). 808	
B. p300 and BTAF1 protein levels in MEF transfected with NTC mimics or miR-132-3p 809	
mimics determined by Western blot. GAPDH was used as a loading control. Right panel 810	
indicates mean + SEM of 4 experiments. 811	
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C. mRNA levels of indicated RP transcripts determined by qRTPCR in MEFs transfected 812	
with NTC siRNA (white) or p300 siRNA (grey). 813	
D. mRNA levels of indicated RP transcripts determined by qRTPCR in MEFs transfected 814	
with NTC siRNA (white) or BTAF1 siRNA (grey). 815	
E. mRNA levels of indicated RP transcripts determined by qRTPCR in MEFs transfected 816	
with NTC or miR-132-3p mimics and NTC siRNA or p300 or BTAF1 siRNAs for 48h. 817	
Levels are normalised to cells transfected with NTC siRNA and NTC mimic.  818	
F. Puromycin incorporation (following 10-minute pulse and 50-minute chase) 819	
determined by western blot in MEFs transfected with NTC or miR-132-3p or miR-212-820	
3p mimics. 821	
Data information: Statistical significance is determined by unpaired t-test from 4-6 822	
experiments. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 823	
 824	
 825	
Figure 4: miR-132 controls the balance between IL-10 and IFNg production in CD4+ 826	
T cells. 827	
A. Percentage of IFNγ+ live TCRβ+ CD4+ cells from L. donovani infected WT (blue) or 828	
miR-132-/- (red) mice, determined by intracellular cytokine staining. Data representative 829	
of 3 independent experiments with 3-5 mice per group. 830	
B. Percentage of IFNγ+/IL-10+ live TCRβ+ CD4+ cells from L. donovani infected WT (blue) 831	
or miR-132-/- (red) mice, determined by intracellular cytokine staining. Data 832	
representative of 3 independent experiments with 3-5 mice per group. 833	
C. IL-10 mRNA levels, determined by RNA-sequencing, in TCRβ+ CD4+ cells purified 834	
from spleens of L. donovani infected WT (blue) or miR-132-/- (red) mice (n=5 per group).  835	
D. Percentage of IFNγ+ WT (blue) or miR-132-/- (red) in vitro polarised Th1 cells (6 days) 836	
in the presence or absence of phenylephrine (PE), determined by intracellular cytokine 837	
staining. 838	
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E. Percentage of IL10+ WT (blue) or miR-132-/- (red) in vitro polarised Th1 cells (6 days) 839	
in the presence or absence of phenylephrine (PE), determined by intracellular cytokine 840	
staining. 841	
F. Total cell counts following in vitro Th1 polarisation (6 days) in the presence or absence 842	
of phenylephrine (PE). For (D-E), cells were purified from 3 mice per group and 6 843	
replicates performed. 844	
 845	
Data information: For (A and B) statistical significance was determined by unpaired t-846	
test. For (D–F), significance was determined with 1-way ANOVA followed by 847	
Bonferroni’s multiple comparison test. * p<0.05, ** p<0.01, *** p<0.001. NS: not 848	
significant. 849	
 850	
 851	
Figure 5: miR-132 promotes protective immunity to L. donovani. 852	
A. Liver LDU (Leishman Donovan units) at day 28 in infected WT mice treated with anti-853	
IL-10R antibody or isotype control antibody (left panel, n=5 mice per group), or at day 854	
21 and day 28 from WT (blue), IL-10+/- (open green circles) and IL-10-/- (filled green 855	
circles) mice (right panel n= 3-6 mice per group) 856	
B. Day 28 splenic parasite burdens expressed as LDU with each data point representing 857	
an individual mouse in WT (blue) and miR-132-/- (miR-132-/-; red) mice. Data from 4 858	
independent infection experiments. 859	
C. Mean WT and miR-132-/- spleen parasite burdens from the 4 independent 860	
experiments shown in (B). Lines link individual experiments. 861	
D. Splenic parasite burdens relative to WT group (WT mean = 1) for each of the 4 862	
experiments shown in (B), with each data point representing individual mouse.  863	
E. Spleen size expressed as % body weight for d0 (naïve) or day 28 L. donovani infected 864	
WT (blue) and miR-132-/- (miR-132-/-; red) mice.  865	
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F. Liver size expressed as % body weight for d0 (naïve) or day 28 L. donovani infected 866	
WT (blue) and miR-132-/- (red) mice.  867	
Data information: Significance determined by unpaired t-test, and in (C) by paired t-test 868	
of mean values. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 869	
 870	
 871	
EXPANDED VIEW FIGURE LEGENDS 872	
 873	
Expanded View Figure EV1: The miR-132/212 cluster regulates RP mRNA levels 874	
in CD4+ T cells from chronically infected spleens. 875	
A. Expression of phosphorylated CREB (Ser133), total CREB and β-actin loading 876	
control in naïve CD4+ T cells cultured for indicated number of hours in presence (+) or 877	
absence (-) of anti-CD3 / anti-CD28, as determined by Western blot. Numbers indicate 878	
intensity normalised to 1 hour unstimulated samples (lane 1) and corrected by β-actin 879	
loading control. Representative of two independent experiments from 3 pooled mice 880	
each. 881	
B. Relative expression of miR-132-3p and miR-212-3p determined by qPCR in naïve 882	
mouse CD4+ T cells stimulated with anti-CD3/anti-CD28 for 18 hours under Th0 (non-883	
polarising; white), Th1 (rIL-12/anti-IL-4; grey) or Th2 conditions (rIL-4/anti-IFNγ; black) 884	
relative to level in naïve cells prior to stimulation. 885	
C. Fold change of all RP transcripts (grey) in Th2 cells compared to naïve CD4 T cells. 886	
Data taken from RNA sequencing experiments described in reference 24. Fold changes 887	
in IL-10 (red) and IL-4 (blue) indicated for comparison. The statistical significance of the 888	
observed up-regulation of RP transcripts in Th1 cells is determined by Chi-squared test. 889	
 890	
Expanded View Figure EV2: The B-TFIID cofactor BTAF1 is a direct miR-132 target 891	
in CD4+ T cells. 892	
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A. Volcano plot of RNAseq gene expression in purified CD62L+ CD44- naïve WT cells 893	
before and after 1 day (18h) stimulation with anti-CD3/anti-CD28. Fold change 894	
determined as log2 mean FPKM (stimulated / pre-stimulation) from 4 WT mice. 895	
Transcripts significantly different (p<0.05) shown in red.  896	
B. Volcano plot of RNAseq gene expression in purified CD62L+ CD44- naïve miR-132-/- 897	
cells before and after 1 day (18h) stimulation with anti-CD3/anti-CD28. Fold change 898	
determined as log2 mean FPKM (stimulated / pre-stimulation) from 4 WT mice. 899	
Transcripts significantly different (p<0.05) shown in red. 900	
C. C. RNAseq gene expression levels of BTAF1 from pre-stimulation (d0), 18h anti-901	
CD3/anti-CD28 (d1) and the spleen of d28 L. donovani infection (Ld), from WT (blue) 902	
and miR-132-/- (red) mice (n=4-5 mice per group). Significance determined by unpaired 903	
t-test as indicated. 904	
D. Schematic of miR-212/132-3p 7mer-m8 site in the 3’UTR of BTAF1 transcript, 905	
showing conservation in human, mouse and chimp. The site is also conserved in, rhesus, 906	
squirrel, rabbit, pig, cow, cat, dog, brown bat, elephant, opossum, macaw and chicken; 907	
but not rat or lizard. 908	
E. Relative luciferase activity in mouse 3T3 cells transfected with plasmid containing 909	
WT (white) or miR-212/132-mutant (grey) BTAF1 3’UTR immediately downstream of 910	
renilla luciferase, in the presence of miR-132-3p or miR-212-3p mimics. Error bars 911	
indicate SEM from eight replicate treatments. Significance determined by unpaired t-912	
test. 913	
F. Nucleotide sequences of mouse mature miRNA derived from miR-212/132 cluster. 914	
Seed sequences indicated in bold. 915	
G. Volcano plots of RNAseq gene expression for transcripts containing a poorly 916	
conserved miR-132-5p site (upper panels) or a broadly evolutionary conserved miR-917	
212-5p site (lower panels). Fold change determined as log2 mean FPKM miR-132-/- 918	
/WT) from 4 WT and miR-132-/- mice. Transcripts significantly different between WT and 919	
miR-132-/- (p<0.05) shown in red. Data compares pre-stimulation naïve CD4 T cells (d0, 920	
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left panels); after 18h in vitro stimulation with anti-CD3/anti-CD28 (d1, middle panels); 921	
and from the spleens of d28 L. donovani-infected mice. Transcripts that are significantly 922	
different (p<0.05) and show >2 fold change in expression are indicated. 923	
H. RNA levels of BACH2 (based on RNA-seq) from pre-stimulation (d0), 18h anti-924	
CD3/anti-CD28 (d1) and the spleen of d28 L. donovani infection (Ld), from WT (blue) 925	
and miR-132-/- (red) mice. Significance determined by unpaired t-test as indicated (n = 926	
4-5 mice per group). 927	
I. Log2 fold change (LFC) in RP genes after 18 hours in vitro stimulation of WT (blue) 928	
or miR-132-/- naïve CD4+ T cells with anti-CD3/anti-CD28. Percentages of up-regulated 929	
and down-regulated transcirpts in WT (40%) and miR-132-/- (61%) cells are shown. 930	
Statistical significance is determined with Chi-squared test. 931	
J) DeltaLFC (LFCmiR-132-/- - LFCWT) after 18 hours in vitro stimulation of WT (blue) or miR-932	
132-/- naïve CD4+ T cells with anti-CD3/anti-CD28. Significance is determined with Chi-933	
squared test. Data information: * p<0.05, ** p<0.01. 934	
 935	
 936	
Expanded View Figure EV3: miR-132 and its targets p300 and BTAF1 control RP 937	
expression. 938	
A. mRNA levels of indicated RP transcripts determined by qRTPCR in MEFs transfected 939	
with NTC mimics (white) or miR-212-3p mimics (grey). Cultures performed in triplicate. 940	
Statistical significance determined by t-test. 941	
B. Protein levels determined by western blot of RPL27 and RPS10 in MEFs transfected 942	
with NTC, miR-132-3p, or miR-212-3p mimics for 48h. 943	
C. Top enriched molecular function GO terms for miR-132/212-3p predicted target 944	
genes. Predictions retrieved from Targetscan, total context score <-0.1. 945	
D. Protein levels determined by western blot of BTAF1 and p300 in EL4 cells transfected 946	
with NTC, miR-132-3p, or miR-212-3p mimics for 48h. 947	
Data information: * p<0.05, ** p<0.01. 948	
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 949	
Expanded View Figure EV4: miR-132 controls the balance between IL-10 and IFNg 950	
production in CD4+ T cells. 951	
A. Intracellular cytokine staining of WT or miR-132-/- splenic live CD45.2+ TCRβ+ CD4+ 952	
cells for IFNγ and IL-10 from d0 naïve and day 28 L. donovani infected mice following 953	
ex vivo stimulation (4hrs) with PMA and ionomycin. 954	
B. Antigen-specific IFNγ and IL-10 production by splenic CD4+ T cells from CD45.2+ L. 955	
donovani-infected WT (blue) or miR-132-/- (red) mice was assessed as described in 956	
materials and methods. Cells were cultured for 3 days in the absence of exogenous 957	
stimulation (“Neg”, open circles) or with parasite antigen (“Ag”, closed circles), after 958	
which cytokine production by CD4+ T cells from infected (“CD45.2”) or naïve mice 959	
(“CD45.1”) was determined. Representative FACS plots for antigen-stimulated CD45.2+ 960	
cells are shown. Significance determined by unpaired t-test, purified CD4+ T cells from 961	
4-5 mice per group. 962	
 963	
Expanded View Figure 5: miR-132 promotes protective immunity to L. donovani. 964	
A. Percentage of IL10+ splenic live CD45.2+ TCRβ+ CD4+ cells for IL-10 in d0 naïve and 965	
d21 in L. donovani-infected WT (blue), IL-10+/- (open green) and IL-10-/- (filled green) 966	
mice. d21 used due to accelerated parasite clearance and immune resolution in IL-10-/- 967	
mice. Significance determined by ANOVA compared to WT group (n=3-5 per group). 968	
B. Percentage of IFNg+ splenic live CD45.2+ TCRβ+ CD4+ cells for IL-10 in d0 naïve and 969	
d21 in L. donovani-infected WT (blue), IL-10+/- (open green) and IL-10-/- (filled green) 970	
mice. d21 used due to accelerated parasite clearance and immune resolution in IL-10-/- 971	
mice. Significance determined by ANOVA compared to WT group. 972	
C. Gating strategy for defining distinct myeloid populations in infected mice shown in C. 973	
NBNT = non-B non-T i.e. B220- CD3- in d0 naïve and d28 infected WT mice. 974	
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D. Total spleen cell numbers or of indicated myeloid populations in d0 naïve and d28 975	
Ld-infected WT (blue) or miR-132-/- (red) mice. Myeloid cells gated as live CD45.2+ CD3- 976	
B220- Ly6G- SSlo singlets then; DC (CD11c+ F4/80- MHCII+); MφA (CD11b+ F4/80+ 977	
CD11c-); MφB (CD11c+ F4/80+ CD11blo); and MφC (CD11c+ F4/80+ CD11bhi). Bars 978	
show mean + SEM. Data pooled from two independent experiments (n=4-5 per group 979	
for each experiment). Significance determined by unpaired t-test as indicated. 980	
E. Total spleen cell numbers or of indicated myeloid populations in d0 naïve and d21 981	
Ld-infected WT (blue), IL-10+/- (open green) and IL-10-/- (filled green) mice (n=3-5 per 982	
group). Myeloid cells gated as in (D). Bars show SEM. Significance determined by one-983	
way ANOVA and is shown compared to WT group. 984	
F. Spontaneous and LPS-induced IL-10 production by indicated spleen myeloid 985	
populations (as in D) from N (naive) and Ld-infected mice (d28), determined by 986	
intracellular cytokine staining. n.d. not detected i.e. cell type absent in naïve mice. 987	
Significance determined by unpaired t-test as indicated, and data pooled from 2 988	
independent experiments each with 3-5 mice per group. Bars show mean + SEM 989	
G. Day 21 liver parasite burdens expressed as LDU (Leishman Donovan units) in WT 990	
(blue) and miR-132-/- (red) mice. Each data point represents an individual mouse. 991	
Significance determined by unpaired t-test 992	
H. Left hand panel: Day 28 liver parasite burdens expressed as LDU (Leishman 993	
Donovan units) in WT (blue) and miR-132-/- (red) mice. Right hand panel shows same 994	
data expressed relative to WT levels (WT mean = 1). Data from 4 independent infection 995	
experiments with 4-5 mice per group per experiment. Significance determined by 996	
unpaired t-test. 997	
I. Day 42 liver parasite burdens expressed as LDU (Leishman Donovan units) in WT 998	
(blue) and miR-132-/- (red) mice. Each data point represents an individual mouse. 999	
Significance determined by unpaired t-test. 1000	
J. J.  Spleen size expressed as % body weight for naïve (= 0 parasite dose) or day 1001	
28 L. donovani infected WT (blue) and miR-132-/- (red) mice. Mice were infected with 10, 1002	
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30 or 100x106 L. donovani amastigotes. Data pooled from 2 independent experiments 1003	
with 3-5 mice per group. Significance determined by unpaired t-test. 1004	
 1005	
K.  Liver size expressed as % body weight for naïve (= 0 parasite dose) or day 28 L. 1006	
donovani infected WT (blue) and miR-132-/- (red) mice. Mice were infected with 10, 30 1007	
or 100x106 L. donovani amastigotes. Data pooled from 2 independent experiments with 1008	
3-5 mice per group. Significance determined by unpaired t-test. Boxes for (J-K) extend 1009	
from 25-75th percentile, whiskers are minimum and maximum values, and horizontal 1010	
lines indicate median 1011	
Data information: * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 1012	
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